SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending following positive Phase 2 trial data for its skin drug, sonelokimab, leading to significant price movement and high volatility. The community is actively discussing the implications of the results, potential buyout scenarios, and the company's overall valuation with some users expressing concerns over a potential offering. Bullish sentiment seems high, but bears warn against high placebo response in study 2.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Despite a recent offering, Cipher Mining is trending as investors see a bullish signal due to its partnership with Google and expansion into high-performance computing. The community is actively discussing the potential for significant growth, especially with the zero-interest funding deal and capped call protections against dilution. Some investors believe Cipher Mining is undervalued, positioning itself as a key player in AI infrastructure rather than just Bitcoin mining.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement of approximately $44 million, leading to significant after-hours price movement. Community discussion revolves around the potential for continued momentum, the impact of the offering, and possible short squeeze opportunities. Some traders are also noting potential dilution from warrants associated with the deal.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a community-driven crypto embracing cannabis culture and freedom. Community members highlight Weedcoin as more than a token; it's a movement for culture, connection, and growth, built on positivity and good vibes. The crypto is seen as a way to connect the cannabis industry with blockchain technology.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

The AdvisorShares MSOS Daily Leveraged ETF ($MSOX) is trending due to renewed speculation around potential cannabis rescheduling and safe banking, with investors actively discussing entry points and potential upside. Bullish sentiment is building as traders anticipate a sector-wide rally, while some express concerns about the ETF's performance and correlation with its underlying assets. Community members are also weighing potential political catalysts and the impact of key figures on the industry's future.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following positive phase 3 trial results for its oral Wegovy pill, showing significant weight loss, which could broaden its market appeal; the community is weighing its potential against competitor Eli Lilly. Community members are also digesting news of job cuts impacting the US obesity education team amid an increasingly competitive GLP-1 market.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Recent buzz around Merus (MRUS) is driven by buyout rumors, with Genmab reportedly leading the acquisition race, exciting retail traders. The community is also discussing Barclays' initiation of an Overweight rating with a $112 price target. Some traders are highlighting the potential of Merus's pipeline and multispecific antibody platform.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to a massive volume spike and significant price volatility, with community members weighing entry points. Discussions revolve around the potential impact of a competitor's ($MLTX) data and speculation about future catalysts. Bullish sentiment is fueled by analyst ratings and price target increases.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals is trending due to the upcoming presentation of topline results from its Phase 2b study of Zelicapavir for RSV in high-risk adults, sparking considerable interest and anticipation within the investment community. Community members are actively discussing potential outcomes, speculating on significant price movements based on positive results, and highlighting unusual options activity that suggests bullish sentiment. The focus remains on the potential of the drug and its impact on the company's valuation.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders weigh the potential impacts of a looming government shutdown and speculate on its effects on the market, particularly regarding the release of upcoming jobs data. Community discussions revolve around potential market reactions, with some anticipating a bullish outcome if a shutdown is averted, while others are bracing for volatility and a possible downturn, especially given concerns about high stock valuations and AI-driven market dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pressure BioSciences, Inc. engages in the manufacture and distribution of infectious disease diagnostic products. It provides pressure-based platform solutions for the worldwide life sciences industry. Its products include barocyclers, barocycler accessories, external pressure calibration device kit, microtubes for barocyclers, microtube accessories for barocyclers, baroshear K45, hub high pressure generators and accessories, HP cell from ISS, RF1700 mini ultra-high pressure pump, shredder SG3 and shredder tubes, and service contracts. It offers its products under the brands Barocycler, PULSE, BioSeq, ProteoSolve, ProteoSolveLRS, Power of PCT, PCT Shredder, HUB440, HUB880, micro- Pestle, PCT-HD, BaroFold, Barozyme, BaroFlex, and Strips. The company was founded by Richard T. Schumacher in August 1978 and is headquartered in Canton, MA.

Current Price	$0.0005
Prev Close	$0.0003
Open	$0.0005
Dividend Yield	N/A
50-Day Moving Average	$0.0006
Beta	18.45
Avg. Volume	4,594.24
PE Ratio	0.00

52-Week High	$0.1075
52-Week Low	$0.0001
Market Capitalization	$20,500.00
EPS (Annual)	N/A
Price to Book	-0.00
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

PBIO
Pressure BioSciences, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest PBIO News

PBIO Pressure BioSciences, Inc.